Welcome to our dedicated page for Genvor SEC filings (Ticker: GNVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The filing record for Genvor Inc. documents material-event disclosures for an OTC biotechnology issuer focused on peptide technology. Recent 8-K reporting covers corporate events, executive or commercial updates, registered office information and public-company disclosure obligations.
Genvor's SEC materials provide formal context for its capital structure, governance and material announcements while company news supplies most of the operating detail. The filings record supports the company's public reporting profile around biotechnology research, partnerships and commercialization activity.
Genvor Incorporated obtained majority written consent on July 17, 2026 to approve four major corporate actions without holding a shareholder meeting. First, it adopted a 2026 Omnibus Equity Incentive Plan authorizing 7,843,555 initial shares for awards, with IPO-related and annual “evergreen” increases tied to fully diluted shares outstanding.
Second, the Board was empowered to implement a reverse stock split of the common stock at any ratio between 1‑for‑2 and 1‑for‑25 any time before July 17, 2027, without changing authorized common shares and rounding fractional shares up to a whole share. Third, an amended and restated charter strengthens director and officer protections, modernizes governance, waives jury trials for certain internal actions, and opts out of a Nevada distribution constraint.
Fourth, amended and restated bylaws centralize control of special meetings and bylaw changes in the Board and executives, lower the quorum to one‑third of voting power, add advance notice rules for nominations and proposals, expand indemnification and advancement rights for directors and officers, and adopt Nevada and federal exclusive forum provisions.
Genvor Incorporated updated its financing arrangement with Evergreen Capital Management through a side letter tied to an existing securities purchase agreement. The original deal allowed up to $800,000 of convertible promissory notes and warrants with an aggregate purchase price of up to $666,668, funded in four tranches.
Under the new letter, Evergreen’s registration and piggyback registration rights were removed, and the total warrants that may be issued rose from 600,000 to up to 1,200,000. Evergreen accelerated funding of the second and third tranches, giving Genvor gross proceeds of $333,334 on June 17, 2026, while the fourth tranche of $166,667 is now exercisable at Evergreen’s option until the note’s maturity.
In connection with this funding, Genvor issued a five-year warrant to Evergreen to purchase up to 300,000 common shares at $1.00 per share, with cashless exercise permitted after six months if the market price exceeds the exercise price and the warrant shares remain unregistered. The warrant and its underlying shares were issued as unregistered securities under Section 4(a)(2) of the Securities Act.
Genvor Inc filed an initial insider ownership report for its Chief Financial Officer, Donald A. Kalkofen. This Form 3 identifies him as an officer of the company but shows no reported stock transactions, option exercises, or other changes in beneficial ownership at this time.
Genvor Incorporated appointed Donald Kalkofen as Chief Financial Officer effective May 18, 2026, initially via a services agreement with Wave Financial Consulting LLC that was amended and restated on May 21, 2026.
Mr. Kalkofen is an experienced biotech CFO with more than 20 years of finance leadership and public company and IPO experience. His amended agreement provides $6,250 in monthly cash compensation and $7,750 in deferred monthly cash compensation through 2026, with cash compensation increasing to $14,000 per month starting January 1, 2027. He is eligible for ten-year options to purchase up to 575,000 shares of common stock, subject to Board approval of an equity plan, shareholder approval, and the effectiveness of a Form S-8 registration statement before the options become exercisable.
Genvor Incorporated reported another pre-revenue quarter and highlighted serious liquidity risks. For the three months ended March 31, 2026, the company generated no revenue and posted a net loss of $429,567, widening from $298,983 a year earlier. For the six-month period, the net loss was $1,005,847, a sharp improvement from $5,300,234 mainly because prior-year stock-based CEO compensation was much higher.
At March 31, 2026, Genvor held only $94,808 in cash, had a working capital deficit of $891,095 and an accumulated deficit of $27,199,153. Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern and plans to rely on additional financings.
During the first half of fiscal 2026, Genvor raised $665,333 through common stock and pre-funded warrant issuances, helping fund operating cash outflows of $594,213. Subsequent to quarter-end, it signed a securities purchase agreement with Evergreen Capital for a convertible note of up to $800,000 and warrants for up to 600,000 shares, and entered a non-binding MOU with Canlab International™ to explore peptide-based products for human health markets.
Genvor Incorporated created a new Series C Preferred Stock class and issued one share under an existing advisory agreement. On May 5, 2026, the company filed a certificate of designation in Nevada setting aside four shares as Series C Preferred Stock with a par value of $0.001 per share.
These shares carry standard voting and dividend rights but preferential conversion rights into common stock. Each Series C share may convert, at the holder’s option, into common stock based on a $300,000 value divided by a specified market price formula that depends on whether Genvor is listed on a national exchange by April 14, 2027. On May 8, 2026, one Series C share was issued to Brio Advisory Group LLC as consideration under an advisory agreement, relying on a private offering exemption from registration.
Genvor Incorporated entered a securities purchase agreement with Evergreen Capital Management LLC, issuing a convertible promissory note of up to $800,000 and warrants to buy up to 600,000 common shares for a purchase price of up to $666,668, paid in four tranches.
The note carries 10% annual interest, matures the earlier of nine months from the April 15, 2026 issue date or an Exchange Listing, and is generally convertible at $1.00 per share, with a lower default conversion formula and a 4.99% beneficial ownership cap. The five-year cashless warrants have a $1.00 initial exercise price, adjustable to the note’s conversion price.
Genvor also signed an Advisory Agreement with Brio Advisory Group, under which Brio provides strategic and financing advice in exchange for preferred stock valued at $300,000 per funding tranche, or equivalent common stock if no Exchange Listing occurs within one year, subject to a minimum $1.00 per-share valuation.
Genvor Inc. reported that Chief Executive Officer Chad Lee Pawlak Sr. received a grant of 250,000 shares of common stock at $0.50 per share. According to the disclosure, this stock award compensates Mr. Pawlak for converting $125,000 of outstanding payables owed to him by the company under a restructured compensation package approved by the board as of December 20, 2024. Following this grant, he directly holds 7,000,000 shares of Genvor common stock.
Pawlak Chad Lee Sr. reported acquisition or exercise transactions in this Form 4 filing.
Genvor Inc Chief Executive Officer Chad Lee Pawlak Sr. received a grant of 250,000 shares of Common Stock as compensation, with a reported price of $0.0000 per share. After this award, he directly holds 6,750,000 Common Stock shares.
The footnote explains this is a compensation award for January–March 2026 under a restructured compensation package approved by the Board of Directors as of December 20, 2024.
Genvor Incorporated reported another quarterly loss and highlighted serious liquidity risks while filing an amendment to correct cover-page checkboxes. For the three months ended December 31, 2025, the company generated no revenue and posted a net loss of $576,280, a sharp improvement from $5,001,251 a year earlier as stock-based compensation and overall operating expenses declined.
Cash was $103,580 at December 31, 2025 with a working capital deficit of about $1.06M, and management stated that these conditions raise substantial doubt about Genvor’s ability to continue as a going concern. To fund operations, the company relied on issuing equity for cash, services, debt conversions, and warrant exercises, bringing common shares to 34,434,938 outstanding as of February 11, 2026.